What is the maximum oral dose of baclofen for treating spasticity, and how should the dose be adjusted in patients with significant renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Oral Baclofen Dose

The maximum oral dose of baclofen is 80 mg daily per FDA labeling, though doses up to 120 mg daily have been used safely in clinical practice for refractory spasticity; in patients with renal impairment (eGFR <60 mL/min/1.73m²), reduce the dose significantly or avoid use entirely if eGFR <30 mL/min/1.73m². 1, 2

Standard Dosing Parameters

The FDA-approved maximum is 80 mg daily, typically divided into multiple doses 1. However, real-world clinical practice demonstrates that some patients require higher doses for adequate spasticity control. Research confirms that doses exceeding 80 mg daily can be safe and effective, with some patients requiring substantially higher doses for symptomatic relief 3. The key limitation is not an arbitrary ceiling but rather individual tolerance and renal function.

Critical Dosing Considerations in Renal Impairment

Baclofen is primarily excreted unchanged by the kidneys, making renal function the most critical factor in dosing decisions 1, 2:

  • eGFR 30-60 mL/min/1.73m²: Reduce dose substantially and monitor closely for toxicity 2
  • eGFR <30 mL/min/1.73m²: Avoid use entirely 2
  • Dialysis-dependent patients: Contraindicated for oral baclofen 2

The evidence strongly indicates that even patients with normal serum creatinine can have subclinical renal insufficiency (reduced creatinine clearance) that predisposes to baclofen accumulation and toxicity 4. This is particularly relevant in spinal cord injury patients who may have neurogenic bladder and compromised renal function.

Pharmacokinetic Pitfalls

High-dose baclofen exhibits different pharmacokinetics than standard dosing 3:

  • Time-to-peak plasma levels are substantially longer than previously reported
  • Plasma half-life is prolonged
  • Blood levels can rise gradually over time even on stable dosing due to impaired renal clearance 3

This means toxicity can develop insidiously in patients who initially tolerated their dose well, especially if renal function deteriorates.

Signs of Baclofen Toxicity

Monitor for:

  • Decreased level of consciousness
  • Respiratory depression
  • Confusion or hallucinations
  • Seizures (particularly with abrupt withdrawal) 1, 5

Withdrawal Precautions

Never discontinue baclofen abruptly except for life-threatening adverse reactions 1. Abrupt withdrawal causes hallucinations and seizures. Taper slowly when discontinuing.

Practical Dosing Algorithm

  1. Assess renal function with calculated creatinine clearance, not just serum creatinine
  2. If eGFR >60: Start standard dosing, can titrate up to 80 mg daily (or higher if needed and tolerated)
  3. If eGFR 30-60: Start at reduced dose (e.g., 50% reduction), titrate slowly with close monitoring
  4. If eGFR <30 or dialysis-dependent: Do not use oral baclofen - consider intrathecal baclofen or alternative antispasmodics 2
  5. Monitor for evolving toxicity even on stable regimens, particularly in patients with neurogenic bladder 4

The 2024 VA/DoD stroke rehabilitation guidelines note that oral baclofen 30-80 mg/day showed comparable efficacy to botulinum toxin for spasticity except in ankle spasticity 6, supporting the conventional dosing range for most patients.

References

Research

Baclofen Toxicity in Kidney Disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018

Research

Clinical and pharmacokinetic aspects of high dose oral baclofen therapy.

The Journal of the American Paraplegia Society, 1992

Research

Baclofen toxicity in a patient with subclinical renal insufficiency.

Archives of physical medicine and rehabilitation, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.